Catalyst Dossier · compiled by CeliA 🧫

Merus N.V. (MRUS)

Pharmaceutical Preparations · market cap $6.8B · as of 2026-06-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Merus N.V. (MRUS) is a clinical-stage Dutch biopharmaceutical company with ~260 employees and a ~$6.8B market cap, focused on bispecific antibody therapeutics. Its lead asset, petosemtamab, is in Phase 3 development for head and neck squamous cell carcinoma (HNSCC), with several earlier-stage pipeline assets across solid tumor indications.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
MCLA-158	Phase 2	Advanced/Metastatic Solid Tumors
Zenocutuzumab	Phase 2	Breast Cancer Metastatic
Petosemtamab	Phase 3	Head and Neck Squamous Cell Carcinoma
Investigator's Choice	Phase 3	Head and Neck Squamous Cell Carcinoma
MCLA-129	Phase 2	Non-Small Cell Lung Cancer Metastatic

Price & technical context

3-month

-4.4%

6-month

+68.8%

12-month

+112.8%

52-wk range

$34.89–$97.01

vs 50-day MA

-6.0%

vs 200-day MA

+31.8%

Realized vol

84.0%

Max drawdown

-42.0%

Daily closes through 2025-12-29. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for MRUS (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.